CoLucid Acquired by Eli Lilly for $960M

Our firm represented CoLucid Pharmaceuticals, Inc., a public biopharmaceutical company, in its acquisition by Eli Lilly and Company for a purchase price of $960 million. CoLucid was founded in 2005 and was developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.